Rakesh Jhunjhunwala holds 1.6 per cent (72,45,605 shares) in this stock as per the March 2021 quarterly figures.
Given the strong volatility in the Indian market due to the second wave of Corona, the giants recommend investing in pharma stocks. There is good news for such investors who follow Rakesh Jhunjhunwala. Market giants recommend buying in Lupine, a pharma stock included in Rakesh Jhunjhunwala’s portfolio.
Market giants say that Lupine’s stock has given a breakout. Since then, this stock has been trading sideways. Market giants are of the opinion that once Lupine’s stock starts rising again, it will be one of the fastest growing stocks.
Avinash Gorakshakar of Profitmart Securities says that the company’s outlook on both margin and demand fronts looks quite good. Apart from this, the fear of Kovid-19 is also in favor of the company. Since Lupine is one of the leading pharma companies in India, in the Corona epidemic period, investors such as Lupine will benefit from the move towards the pharma sector.
Moreover, as this stock is included in Rakesh Jhunjhunwala’s portfolio, it is natural for retail investors to be interested in it. Avinash Gorakshakara recommends investing in this stock from both short-term and long-term perspective.
Ravi Singhal of GCL Securities also says that Lupine gave a breakout about 1 month ago, but after that the sideways is visible. It will be the fastest moving stock in the Indian market after just one trigger. Lupine recommends buying with a stoploss below Rs 970 for a target of Rs 1270 for a period of 3 months.
Rakesh Jhunjhunwala holds 1.6 per cent (72,45,605 shares) in this company as per the March 2021 quarterly figures.
